The news of Sun Pharmaceutical considering a proposal to acquire all outstanding ordinary shares of Taro Pharmaceuticals has led to an increase in Taro's share price. This is because acquisitions typically result in a premium being paid for the target company's shares, which would benefit Taro's shareholders. The potential acquisition is highly relevant and important for Taro's investors, as it could significantly impact the company's valuation and future prospects.